Recommended Topic Related To:

Soliris

"The Centers for Disease Control and Prevention has identified a cluster of newborns in Tennessee with late vitamin K deficiency bleeding (VKDB). VKDB is a serious, but preventable bleeding disorder that can cause bleeding in the brain. In each"...

Soliris

Soliris

Soliris Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Soliris (eculizumab) is used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinemia (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). It is a monoclonal antibody that binds to proteins in the blood that can destroy red blood cells in people with a genetic condition that affects the natural defenses of red blood cells. Common side effects include headache, tiredness, nausea, or muscle pain.

The Soliris therapy dosing regimen to treat PNH in adults consists of: 600 mg weekly for the first 4 weeks, followed by 900 mg for the fifth dose 1 week later, then 900 mg every 2 weeks thereafter. The dosing regimen to treat aHUS in adults consists of: 900 mg weekly for the first 4 weeks, followed by 1200 mg for the fifth dose 1 week later, then 1200 mg every 2 weeks thereafter. Other drugs may interact with Soliris. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, Soliris should be used only when prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Our Soliris (eculizumab) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Soliris in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • severe headache with fever, confusion, purple spots on the skin, nausea or vomiting, and/or seizure (convulsions);
  • stiffness in your neck or back;
  • sensitivity to bright light;
  • high fever (103 degrees or higher), chills, body aches, flu symptoms;
  • pain or burning when you urinate;
  • any signs of a new illness or infection; or
  • signs that the medication is not working (pale skin, easy bruising, weakness, dark urine, feeling short of breath, or sudden numbness, severe headache, deep leg pain, or problems with vision, speech, or balance).

Less serious side effects may include:

  • nausea;
  • diarrhea;
  • mild headache;
  • runny nose, sore throat; or
  • back pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Soliris (Eculizumab) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Soliris Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Warning section.

Headache, tiredness, nausea, or muscle pain may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: signs of infection (e.g., fever, persistent sore throat).

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Soliris (Eculizumab)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Soliris FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Clinical Trial Experience

Meningococcal infections are the most important adverse reactions experienced by patients receiving Soliris. In PNH clinical studies, two patients experienced meningococcal sepsis. Both patients had previously received a meningococcal vaccine. In clinical studies among patients without PNH, meningococcal meningitis occurred in one unvaccinated patient. Meningococcal sepsis occurred in one previously vaccinated patient enrolled in the retrospective aHUS study during the post-study follow-up period [see WARNINGS AND PRECAUTIONS].

PNH

The data described below reflect exposure to Soliris in 196 adult patients with PNH, age 18-85, of whom 55% were female. All had signs or symptoms of intravascular hemolysis. Soliris was studied in a placebo-controlled clinical study (in which 43 patients received Soliris and 44, placebo); a single arm clinical study and a long term extension study. 182 patients were exposed for greater than one year. All patients received the recommended Soliris dose regimen.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 4 summarizes the adverse reactions that occurred at a numerically higher rate in the Soliris group than the placebo group and at a rate of 5% or more among patients treated with Soliris.

Table 4: Adverse Reactions Reported In 5% Or More Of Soliris Treated Patients And Greater Than Placebo In The Controlled Clinical Study

Reaction Soliris
N = 43
N (%)
Placebo
N = 44
N (%)
Headache 19 (44) 12 (27)
Nasopharyngitis 10 (23) 8 (18)
Back pain 8 (19) 4 (9)
Nausea 7 (16) 5 (11)
Fatigue 5 (12) 1 (2)
Cough 5 (12) 4 (9)
Herpes simplex infections 3 (7) 0
Sinusitis 3 (7) 0
Respiratory tract infection 3 (7) 1 (2)
Constipation 3 (7) 2 (5)
Myalgia 3 (7) 1 (2)
Pain in extremity 3 (7) 1 (2)
Influenza-like illness 2 (5) 1 (2)

In the placebo-controlled clinical study, serious adverse reactions occurred among 4 (9%) patients receiving Soliris and 9 (21%) patients receiving placebo. The serious reactions included infections and progression of PNH. No deaths occurred in the study and no patients receiving Soliris experienced a thrombotic event; one thrombotic event occurred in a patient receiving placebo.

Among 193 patients with PNH treated with Soliris in the single arm, clinical study or the follow-up study, the adverse reactions were similar to those reported in the placebo-controlled clinical study. Serious adverse reactions occurred among 16% of the patients in these studies. The most common serious adverse reactions were: viral infection (2%), headache (2%), anemia (2%), and pyrexia (2%).

aHUS

The safety of Soliris therapy in patients with aHUS was evaluated in two prospective, single-arm studies (aHUS Studies 1 and 2) and one retrospective study (aHUS Study 3). The data described below were derived from 37 adult and adolescent patients with aHUS enrolled in aHUS Study 1 and aHUS Study 2. All patients received the recommended dosage of Soliris. Median exposure was 38 weeks (range: 2-64 weeks).

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 5 summarizes all adverse events reported in at least 10% of patients in aHUS Studies 1 and 2 combined.

Table 5: Per Patient Incidence of Adverse Events in Adult and Adolescent Patients Enrolled in aHUS Study 1 and aHUS Study 2 Separately and in Total

MedDRA ver. 11.0 Number (%) of Patients
Study 1 (n=17) Study 2 (n=20) Total (n=37)
Vascular Disorders
  Hypertensiona 8(47) 5 (25) 13 (35)
Infections and Infestations
  Upper respiratory tract infectionb 5 (29) 8 (40) 13(35)
  Urinary tract infection 4 (24) 2 (10) 6 (16)
Gastrointestinal Disorders
  Diarrhea 6 (35) 6 (30) 12 (32)
  Vomiting 5 (29) 3 (15) 8 (22)
  Nausea 4 (24) 3 (15) 7 (19)
  Abdominal pain 0 4 (20) 4 (11)
Nervous System Disorders
  Headache 7 (41) 4 (20) 11 (30)
Blood and Lymphatic System Disorders
  Anemia 6 (35) 3 (15) 9 (24)
  Leukopenia 4 (24) 2 (10) 6 (16)
Psychiatric Disorders
  Insomnia 4 (24) 1 (5) 5 (14)
Respiratory, Thoracic and Mediastinal Disorders
  Cough 2 (12) 3 (15) 5 (14)
  Pharyngolaryngeal pain 1 (6) 4 (20) 5 (14)
General Disorders and Administration Site Conditions
  Fatigue 3 (18) 1 (5) 4 (11)
  Peripheral edema 3 (18) 1 (5) 4 (11)
  Pyrexia 3 (18) 1 (5) 4 (11)
Ear and Labyrinth Disorders
  Vertigo 1 (6) 3 (15) 4 (11)
Musculoskeletal and Connective Tissue Disorders
  Pain in extremity 1 (6) 3 (15) 4 (11)
a includes the preferred terms hypertension, accelerated hypertension, and malignant hypertension.
b includes the preferred terms upper respiratory tract infection and nasopharyngitis.

In aHUS Studies 1 and 2 combined, 54% (20/37) of patients experienced a serious adverse event (SAE). The most commonly reported SAEs were hypertension (16%) and infections (14%). One patient discontinued Soliris due to adverse events deemed unrelated to Soliris.

Analysis of retrospectively collected adverse event data from pediatric and adult patients enrolled in aHUS Study 3 (N=30) revealed a safety profile that was similar to that which was observed in the two prospective studies. aHUS Study 3 included 19 pediatric patients less than 18 years of age. Overall, the safety of Soliris in pediatric patients with aHUS enrolled in Study 3 appeared similar to that observed in adult patients. The most common ( ≥ 15%) adverse events occurring in pediatric patients are presented in Table 6.

Table 6: Adverse Reactions Occurring in at Least 15% of Patients Less than 18 Years of Age Enrolled in aHUS Study 3

MedDRA ver. 11.0 Number (%) of Patients
< 2 yrs
(n=5)
2 to < 12 yrs
(n=10)
12 to < 18 yrs
(n=4)
Total
(n=19)
General Disorders and Administration Site Conditions
Pyrexia 4 (80) 4 (60) 1 (25) 9 (47)
Gastrointestinal Disorders
Diarrhea 1 (20) 4 (40) 1 (25) 6 (32)
Vomiting 2 (40) 1 (10) 1 (25) 4 (21)
Infections and Infestations
Upper respiratory tract infectiona 2 (40) 3 (30) 1 (25) 6 (32)
Respiratory, Thoracic and Mediastinal Disorders
Cough 3 (60) 2 (20) 0 (0) 5 (26)
Nasal congestion 2 (40) 2 (20) 0 (0) 4 (21)
Cardiac Disorders
Tachycardia 2 (40) 2 (20) 0 (0) 4 (21)
a includes the preferred terms upper respiratory tract infection and nasopharyngitis.

Immunogenicity

As with all proteins there is a potential for immunogenicity. The immunogenicity of Soliris has been evaluated using two different immunoassays for the detection of anti-eculizumab antibodies: a direct enzyme-linked immunosorbent assay (ELISA) using the Fab fragment of eculizumab as target was used for the PNH indication; and an electro-chemiluminescence (ECL) bridging assay using the eculizumab whole molecular as target was used for the aHUS indication. Low titers of antibodies to Soliris were detected in 3/196 (2%) of all PNH patients treated with Soliris by the ELISA assay. In patients with aHUS treated with Soliris, antibodies to Soliris were detected in 1/37 (2.7%) by the ECL assay. An ECL based neutralizing HAHA assay with a low sensitivity of 2 mcg/mL was performed to detect neutralizing antibodies for the 37 patients with aHUS. No neutralizing activity to Soliris was detected in patients with aHUS treated with Soliris. No apparent correlation of antibody development to clinical response was observed in both indications. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to Soliris in an ELISA based assay and/or an ECL based assay are highly dependent on the sensitivity and specificity of the assay used. Additionally, the observed incidence of antibody positivity in the assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to Soliris with the incidence of antibodies to other products may be misleading.

Postmarketing Experience

Cases of serious or fatal meningococcal infections have been reported.

Read the entire FDA prescribing information for Soliris (Eculizumab) »

A A A

Soliris - User Reviews

Soliris User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Soliris sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations